Core Viewpoint - Sunshine Nuohuo (688621.SH) aims to enhance its strategic layout in in vivo CAR-T cell therapy and nucleic acid drugs by investing 15 million yuan to subscribe for an additional registered capital of 110,556 yuan in Yuanma Zhiyao [1] Group 1: Company Overview - Yuanma Zhiyao is founded by a team of industry experts and returnee PhDs with diverse backgrounds, focusing on the innovation and research of circular mRNA in vivo CAR-T nucleic acid drugs [1] - The company aims to achieve "cell therapy effects" through "nucleic acid drug forms," intending to disrupt the commercialization challenges of CAR-T therapy [1]

智通财经APP讯，阳光诺和(688621.SH)公告，公司拟以自有资金出资1500万元，认缴元码智药新增注 册资本 11.0556 万元，增资完成后将持有其8.20%的股权。该事项旨在推进在体内CAR-T细胞治疗与核 酸药物领域的整体战略布局。 ...